To the Editor We read with interest the noninferiority randomized clinical trial (RCT) by Tarvainen et al1 comparing Hydrocortisone vs Pasireotide in Reducing Pancreatic Surgery Complications (HYPAR). Somatostatin analogues have been advocated in the prophylactic setting to reduce the risk of postoperative pancreatic fistula (POPF). Therefore, any trial that was designed to test the noninferiority of a newer treatment against a somatostatin analogue should have been powered on this outcome. Additionally, per protocol analysis that includes all patients who satisfactorily complied with treatment are usually preferred in noninferiority trials because it is more likely to clearly detect any treatment differences. At the very least, this should be reported alongside the intention-to-treat analysis.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Adiamah A, Kushairi A, Gomez D. The Hydrocortisone vs Pasireotide in Reducing Pancreatic Surgery Complications Noninferiority Trial: Comparing Apples and Pears? JAMA Surg. 2020;155(10):994–995. doi:10.1001/jamasurg.2020.1998
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: